DURHAM – Two life science firms with a big presence in the Triangle are teaming up for a joint research project targeting gene editing treatments.
Novo Nordisk and bluebird bio announced the three-year agreement Wednesday.
Financial terms were not disclosed.
Among the early targets is haemophilia A.
A successful treatment could mean “a lifetime free of factor replacement therapy,” according to the firms.
“The research collaboration will utilize bluebird bio’s proprietary mRNA-based megaTA technology that has the potential to provide a highly specific and efficient way to silence, edit or insert genetic components,” the companies said.
“Aligned with Novo Nordisk’s haemophilia portfolio, the research collaboration will initially focus on correcting FVIII-clotting factor deficiency, with the potential to explore additional therapeutic targets.”
